Drugs Made In America Acquisition (DMAAU) EPS (Weighted Average and Diluted) (2025)

Drugs Made In America Acquisition (DMAAU) reported EPS (Weighted Average and Diluted) of -$0.09 for Q4 2025, down 223.55% quarter-over-quarter from $0.07 in Q3 2025.

Drugs Made In America Acquisition (DMAAU) EPS (Weighted Average and Diluted) (2025) Analysis & Trends

Drugs Made In America Acquisition has reported EPS (Weighted Average and Diluted) for 1 years, with the latest figure at -$0.09 in Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) changed N/A year-over-year to -$0.09; the trailing twelve-month figure through Dec 2025 stood at $0.19 (changed N/A YoY), and the FY2025 full-year result was $0.19, up 733.33% from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 stood at -$0.09, down from $0.07 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.07 in Q2 2025, with the low at -$0.09 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - 0.07
2 Berto Acquisition 312.46 Mn 312.46 Mn - 0.06
3 Centurion Acquisition 311.65 Mn 311.65 Mn - 0.07
4 GP-Act III Acquisition 311.36 Mn 311.36 Mn - 0.08
5 Churchill Capital Corp IX 310.79 Mn 310.79 Mn - 0.04
6 WEN Acquisition 309.15 Mn 309.15 Mn - 0.08
7 Bold Eagle Acquisition 275.54 Mn 275.54 Mn - 0.07
8 Soulpower Acquisition 264.91 Mn 264.91 Mn - 0.05
9 BTC Development 262.16 Mn 262.16 Mn - 0.05
10 Drugs Made In America Acquisition - - - -0.09

Historic Data

Download Data
DateValue
Dec 31, 2025 -0.09
Sep 30, 2025 0.07
Jun 30, 2025 0.07
Mar 31, 2025 0.05